IDX.AU Integral Diagnostics Ltd
- Market cap
- AUD 660M
- P/E
- 29.4x
- P/B
- 0.98x
- ROE
- 3.2%
- Dividend yield
- 3.93%
- Fundamental score
- 1.8/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is IDX.AU undervalued?
Graham numberIDX.AU trades 12.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Integral Diagnostics Ltd fundamental analysis
9 of 22 checks passedROE 0/2
Low return on equity (3.2%), below 10%.
ROA 1/1
Return on assets (1.5%) is above the industry median (-0.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (286.6%) is above the 5-year average (-17.8% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (286.6%) is above the industry median (-1.5%).
Revenue Growth 2/2
Revenue grew 21.5% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (88.3%), up to 100%.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is 2.0x against interest expense, below 5x.
PE vs Market 0/1
PE (29.4x) is above the market median (15.0x).
PE vs Industry 0/1
PE (29.4x) is above the industry median (27.1x).
PBV 1/1
Price to book (1.0x) is below the industry median (2.0x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 28.7, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (3.9%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 0/1
Payout ratio is 118.2%, above 90% of earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Integral Diagnostics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Integral Diagnostics Ltd
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, allied health professionals, and patients in Australia and New Zealand. It offers medical diagnostic imaging services, such as magnetic resonance imaging, computed tomography, mammography, ultrasound, and radiography, as well as nuclear medicine, including positron emission tomography. The company was founded in 1967 and is headquar…
Full company profileIntegral Diagnostics Ltd financial statements
Integral Diagnostics Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 180M | 189M | 232M | 274M | 349M | 359M | 440M | 470M | 627M | 789M |
| Gross Profit | 65.3M | 71.2M | 91.0M | 72.1M | 92.2M | 83.8M | 97.8M | 447M | 599M | 169M |
| Operating Income | 23.7M | 28.5M | 37.9M | 38.4M | 47.9M | 38.4M | 40.1M | 42.2M | 57.5M | 67.7M |
| EBITDA | 34.0M | 34.5M | 50.3M | 69.5M | 88.9M | 69.9M | 92.7M | 12.3M | 90.7M | 142M |
| Net Income | 15.5M | 15.1M | 21.0M | 23.0M | 31.3M | 14.6M | 25.0M | -60.7M | 4.67M | 21.9M |
| EPS | 0.11 | 0.10 | 0.10 | 0.11 | 0.16 | 0.07 | 0.11 | -0.26 | 0.02 | 0.06 |
| Balance Sheet | ||||||||||
| Total Assets | 190M | 196M | 315M | 587M | 655M | 783M | 839M | 744M | 1.43B | 1.46B |
| Total Liabilities | 100M | 102M | 187M | 359M | 400M | 436M | 466M | 443M | 733M | 779M |
| Shareholders' Equity | 90.4M | 93.4M | 127M | 228M | 255M | 347M | 373M | 302M | 693M | 676M |
| Cash & Short-term Investments | 24.2M | 20.8M | 21.0M | 58.0M | 62.2M | 123M | 33.9M | 42.4M | 52.1M | 51.3M |
| Total Debt | 72.9M | 65.3M | 139M | 278M | 308M | 341M | 365M | 356M | 585M | 597M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 22.7M | 26.5M | 33.9M | 54.3M | 69.6M | 37.1M | 71.4M | 66.2M | 73.8M | 95.2M |
| Capital Expenditure | 11.7M | 11.6M | 18.7M | 25.9M | 20.3M | 27.8M | 44.0M | 23.9M | 59.8M | 49.6M |
| Free Cash Flow | 11.1M | 14.9M | 15.3M | 28.4M | 49.3M | 9.33M | 27.4M | 42.3M | 14.0M | 45.6M |
| Ratios | ||||||||||
| ROE | 17.1% | 16.1% | 16.5% | 10.1% | 12.3% | 4.2% | 6.7% | -20.1% | 0.7% | 3.2% |
| ROA | 8.1% | 7.7% | 6.7% | 3.9% | 4.8% | 1.9% | 3.0% | -8.2% | 0.3% | 1.5% |
| Net Profit Margin | 8.6% | 8.0% | 9.0% | 8.4% | 9.0% | 4.1% | 5.7% | -12.9% | 0.7% | 2.8% |
| Debt to Equity | 0.81x | 0.70x | 1.09x | 1.22x | 1.21x | 0.98x | 0.98x | 1.18x | 0.84x | 0.88x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Integral Diagnostics Ltd dividends
- Dividend yield
- 3.93%
- Forward dividend
- 0.09 AUD
- Payout ratio
- 118.2%
- Ex-dividend date
- Aug 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | AUD 25.9M | 0.07 | 118.2% |
| 2025 | AUD 15.5M | 0.05 | 330.8% |
| 2024 | AUD 13.8M | 0.06 | - |
| 2023 | AUD 12.6M | 0.05 | 50.5% |
| 2022 | AUD 20.9M | 0.10 | 142.9% |
| 2021 | AUD 17.9M | 0.09 | 57.2% |
| 2020 | AUD 18.0M | 0.09 | 78.3% |
| 2019 | AUD 14.0M | 0.07 | 66.8% |
| 2018 | AUD 11.6M | 0.08 | 76.9% |
| 2017 | AUD 10.2M | 0.07 | 65.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Integral Diagnostics Ltd
- Insiders 4.90%
- Institutions 49.63%
- Public & others 45.47%
- Shares outstanding 374M
- Free float 339M
Top funds holding IDX.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 2.04M | 1.02% | - | Oct 2020 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 937K | 0.47% | - | Dec 2020 |
| iShares MSCI EAFE Small Cap ETF | 677K | 0.34% | - | Feb 2021 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 387K | 0.19% | - | Oct 2020 |
| DFA Asia Pacific Small Company Series | 312K | 0.16% | - | Jan 2021 |
| WisdomTree Tr-WisdomTree International Small Cap Dividend Fd | 274K | 0.14% | - | Feb 2021 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 200K | 0.10% | - | Nov 2020 |
| DFA International Core Equity Portfolio | 191K | 0.10% | - | Jan 2021 |
| College Retirement Equities Fund-Stock Account | 151K | 0.08% | - | Dec 2020 |
| Vanguard International Stock Index-Pacific Stock Index | 124K | 0.06% | - | Jan 2021 |
Integral Diagnostics Ltd company profile
- Company name
- Integral Diagnostics Ltd
- Ticker
- IDX.AU
- ISIN
- AU000000IDX2
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 3,049
- Fiscal year end
- June
- Address
- 288 Victoria Parade, East Melbourne, VIC, Australia, 3002
- Phone
- 61 3 5339 0704
- Website
- integraldiagnostics.com.au
About Integral Diagnostics Ltd
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, allied health professionals, and patients in Australia and New Zealand. It offers medical diagnostic imaging services, such as magnetic resonance imaging, computed tomography, mammography, ultrasound, and radiography, as well as nuclear medicine, including positron emission tomography. The company was founded in 1967 and is headquartered in East Melbourne, Australia.
Integral Diagnostics Ltd management
6- Mr. Jason Martinez B.Com.MD, CEO & Director
- Ms. Jennifer Margaret Martin B.Acc ACAChief Financial Officer
- Mr. Julian GullyChief Information Officer
- Ms. Melissa WongChief People Officer
- Dr. Tony ChenChief Medical Officer
- Mr. John Merity B.A., L.L.B.Company Secretary